News / Taiwan / cnyes
Medigen Vaccine Biologics Reports 416% Surge in August Revenue
Health Technology · Biotechnology · cnyes · 2026-09-10
6547
Medigen Vaccine Biologics (6547) announced an August revenue of NT$236 million, marking a significant year-on-year increase of 416.86%.
What Happened
Revenue Growth: Medigen Vaccine Biologics (6547) reported August 2026 revenue of NT$236 million, reflecting a massive year-on-year increase of 416.86% and a monthly growth of 399.01%.
Year-to-Date Performance: The cumulative revenue for the first eight months of 2026 reached NT$505 million, representing a year-to-date growth rate of 39.45%.
Stock Performance: The company's stock price currently stands at NT$68.1, with a 10.73% gain over the past five days, outperforming the broader biotech sector index.
Business Scope: Medigen operates within the biotechnology sector, specializing in the research, development, and manufacturing of vaccines and biological agents.